Analyst sees 'huge potential' in Amazon's foray into healthcare

A question that is arising with increasing frequency when the widely-discussed topic of US drug prices comes up in public forums is whether technology is the only force that can bring radical disrupt.

If, among the many tech companies that are entering this space with bold ambitions, the online retail giant Amazon (Nasdaq: AMZN) cannot bring about change with its reach to consumers, successful e-commerce model and financial clout, then perhaps no-one can.

The company’s move into healthcare is being closely watched by all players in the current ecosystem and one expert who believes that Amazon is about to make huge strides in the sector is Pavan Kottamasu, senior pharma analyst at the data and analytics company GlobalData.